Adeno associated viral vector-mediated expression of somatostatin in rat hippocampus suppresses seizure development

Neuroscience Letters

Volumn 509, Issue 2, 2012, Pages 87-91

  Zafar, Rabia ^a,b   King, Michael Alan ^a   Carney, Paul Richard ^a,b,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c University of Florida   (United States)

Author keywords

Adeno associated viral vector; Electrical kindling; Gene therapy; Neuropeptides; Somatostatin; Temporal lobe epilepsy

Indexed keywords

PARVOVIRUS VECTOR; SOMATOSTATIN;

ADENO ASSOCIATED VIRUS; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ELECTROSTIMULATION; GENE EXPRESSION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; KINDLING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEIZURE; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

AMYGDALA; ANIMALS; ANTICONVULSANTS; DEPENDOVIRUS; EPILEPSY; GENETIC THERAPY; GENETIC VECTORS; HIPPOCAMPUS; KINDLING, NEUROLOGIC; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; SOMATOSTATIN;

EID: 84856390334     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.12.035     Document Type: Article

References (37)

1. Bertram E. The relevance of kindling for human epilepsy. Epilepsia 2007, 48(Suppl. 2):65-74.
2. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973, 179:77-79.
3. Buckmaster P.S., Dudek F.E. Neuron loss, granule cell axon reorganization, and functional changes in the dentate gyrus of epileptic kainate-treated rats. J. Comp. Neurol. 1997, 385:385-404.
4. Buckmaster P.S., Otero-Corchon V., Rubinstein M., Low M.J. Heightened seizure severity in somatostatin knockout mice. Epilepsy Res. 2002, 48:43-56.
5. Choi I.S., Cho J.H., Lee M.G., Choi B.J. Pilocarpine-induced seizure susceptibility in rats following prenatal methylazoxymethanol treatment. Biol. Pharm. Bull. 2005, 28:1408-1413.
6. Davies P., Katzman R., Terry R.D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature 1980, 288:279-280.
7. Davis K.L., Mohs R.C., Marin D.B., Purohit D.P., Perl D.P., Lantz M., Austin G., Haroutunian V. Neuropeptide abnormalities in patients with early Alzheimer disease. Arch. Gen. Psychiatry 1999, 56:981-987.
8. Dudek F.E. Commentary: a skeptical view of experimental gene therapy to block epileptogenesis. Neurotherapeutics 2009, 6:319-322.
9. Engel J., Pedley T.A. What is Epilepsy? 2005, Lippincott-Raven, Philadelphia, pp. 11.
10. Haberman R.P., Samulski R.J., McCown T.J. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat. Med. 2003, 9:1076-1080.
11. Jiao Y., Sun Z., Lee T., Fusco F.R., Kimble T.D., Meade C.A., Cuthbertson S., Reiner A. A simple and sensitive antigen retrieval method for free-floating and slide-mounted tissue sections. J. Neurosci. Methods 1999, 93:149-162.
12. Lin E.J., Richichi C., Young D., Baer K., Vezzani A., During M.J. Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur. J. Neurosci. 2003, 18:2087-2092.
13. Lopes da Silva F.H., Gorter J.A. Plasticity and Epileptogenesis. Encyclopedia of Basic Epilepsy Research 2009, 221-227. Elsevier, Oxford. P.A. Schwartzkroin (Ed.).
14. P.A. Lukasiuk K., Seizures, Seizure-induced gene expression.
15. Lundstrom L., Elmquist A., Bartfai T., Langel U. Galanin and its receptors in neurological disorders. Neuromol. Med. 2005, 7:157-180.
16. Mazarati A., Langel U., Bartfai T. Galanin: an endogenous anticonvulsant?. Neuroscientist 2001, 7:506-517.
17. Mazarati A., Wasterlain C.G. Anticonvulsant effects of four neuropeptides in the rat hippocampus during self-sustaining status epilepticus. Neurosci. Lett. 2002, 331:123-127.
18. McCown T.J. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol. Ther. 2006, 14:63-68.
19. Morimoto K., Fahnestock M., Racine R.J. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog. Neurobiol. 2004, 73:1-60.
20. Pitkanen A., Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol. 2011, 10:173-186.
21. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32:281-294.
22. Reichlin S. Somatostatin. N. Engl. J. Med. 1983, 309:1495-1501.
23. Robbins R.J., Brines M.L., Kim J.H., Adrian T., de Lanerolle N., Welsh S., Spencer D.D. A selective loss of somatostatin in the hippocampus of patients with temporal lobe epilepsy. Ann. Neurol. 1991, 29:325-332.
24. Sato M., Racine R.J., McIntyre D.C. Kindling: basic mechanisms and clinical validity. Electroencephalogr. Clin. Neurophysiol. 1990, 76:459-472.
25. Schwarzer C., Sperk G., Samanin R., Rizzi M., Gariboldi M., Vezzani A. Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. Brain Res. Brain Res. Rev. 1996, 22:27-50.
26. Schwarzer C., Williamson J.M., Lothman E.W., Vezzani A., Sperk G. Somatostatin neuropeptide Y, neurokinin B and cholecystokinin immunoreactivity in two chronic models of temporal lobe epilepsy. Neuroscience 1995, 69:831-845.
27. Sharma A.K., Reams R.Y., Jordan W.H., Miller M.A., Thacker H.L., Snyder P.W. Mesial temporal lobe epilepsy: pathogenesis, induced rodent models and lesions. Toxicol. Pathol. 2007, 35:984-999.
28. Sloviter R.S. Decreased hippocampal inhibition and a selective loss of interneurons in experimental epilepsy. Science 1987, 235:73-76.
29. Sorensen A.T., Nikitidou L., Ledri M., Lin E.J., During M.J., Kanter-Schlifke I., Kokaia M. Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp. Neurol. 2009, 215:328-333.
30. Sperk G., Marksteiner J., Gruber B., Bellmann R., Mahata M., Ortler M. Functional changes in neuropeptide Y- and somatostatin-containing neurons induced by limbic seizures in the rat. Neuroscience 1992, 50:831-846.
31. Sun C., Mtchedlishvili Z., Bertram E.H., Erisir A., Kapur J. Selective loss of dentate hilar interneurons contributes to reduced synaptic inhibition of granule cells in an electrical stimulation-based animal model of temporal lobe epilepsy. J. Comp. Neurol. 2007, 500:876-893.
32. Tallent M.K., Siggins G.R. Somatostatin acts in CA1 and CA3 to reduce hippocampal epileptiform activity. J. Neurophysiol. 1999, 81:1626-1635.
33. Tallent M.K., Siggins G.R. Somatostatin depresses excitatory but not inhibitory neurotransmission in rat CA1 hippocampus. J. Neurophysiol. 1997, 78:3008-3018.
34. Tallent M.K., Qiu C. Somatostatin: an endogenous antiepileptic. Mol. Cell. Endocrinol. 2008, 286:96-103.
35. Tuunanen J., Halonen T., Pitkanen A. Decrease in somatostatin-immunoreactive neurons in the rat amygdaloid complex in a kindling model of temporal lobe epilepsy. Epilepsy Res. 1997, 26:315-327.
36. Vezzani A., Hoyer D. Brain somatostatin: a candidate inhibitory role in seizures and epileptogenesis. Eur. J. Neurosci. 1999, 11:3767-3776.
37. Woldbye D.P., Larsen P.J., Mikkelsen J.D., Klemp K., Madsen T.M., Bolwig T.G. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat. Med. 1997, 3:761-764.